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Intravenous infusion of physostigmine (a centrally active anticholinesterase agent) in normal subjects leads 
to a syndrome of psychomotor inhibition; this has been proposed as a model for selected symptoms of 
depression. In view of its similarity to the negative schizophrenic syndrome, we compared the ‘physostigmine 
syndrome’ to the negative symptom profile by evaluating the behavioral effects of intravenous physostigmine 
infusion in seven normal volunteers. Observer ratings and self description revealed significant withdrawal, 
apathy, alogia, lethargy, decreased energy, slowed thoughts, diminished affective responsivity, and reduced 
hedonic capacity. Subjects did not report sadness, ideas of hopelessness, worthlessness, or guilt. These 
findings support the implication of cholinergic hyperactivity as one mechanism in the pathophysiology of 
negative schizophrenic symptoms. 
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INTRODUCTION 
Despite the renewed interest in the negative symp- 
toms of schizophrenia (Strauss et al., 1974; Crow, 
1980; Andreasen, 1982), their underlying patho- 
physiology remains obscure. Although a variety of 
structural, neurochemical, developmental, and 
other abnormalities have been implicated in the 
production of negative symptoms (Greden and 
Tandon, 1990), none of these hypotheses can be 
regarded as proven. We have recently suggested 
that cholinergic hyperactivity may be one mecha- 
nism involved in the production of negative schizo- 
phrenic symptoms (Tandon and Greden, 1989). 
We sought to evaluate this hypothesis by studying 
the behavioral effects of a cholinergic agent in 
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normal volunteers; the hypothesis would predict 
that these behavioral effects would resemble the 
negative symptom profile. 
Intravenous infusion of physostigmine, a 
centrally active anticholinesterase agent, in normal 
controls leads to a behavioral syndrome charac- 
terized by withdrawal, lethargy, apathy and 
reduced energy, slowed thoughts, decreased 
thoughts, motor retardation and decreased monot- 
onous speech (Modestin et al., 1973; Davis et al., 
1976; Risch et al., 1981; Janowsky et al., 1986). In 
view of the similarity of these behavioral effects to 
selected clinical features of depression, these find- 
ings have been used to implicate cholinergic dysreg- 
ulation in mood disorders (Janowsky et al., 1974; 
Risch et al., 1981; Dilsaver, 1986). Parallels 
between the physostigmine profile and the negative 
schizophrenic syndrome also appeared striking to 
us upon initial consideration. We conducted the 
present study in an attempt to examine in more 
detail the ‘physostigmine syndrome’ and to com- 




Seven healthy male subjects between the ages of 
21 and 45 were recruited by newspaper advertise- 
ments for participation in this study. We screened 
each individual by questionnaire, telephone, and 
personal interview, and selected only those without 
any personal or family history of psychiatric disor- 
der. There was no history of substance abuse, and 
none of the participants suffered from any physical 
disorder or had taken’any medications for at least 
the preceeding 2 weeks. All were familiarized with 
the study design and provided informed consent. 
Each subject received a compensation of $50.00 
for participation in the study. Neuroendocrine 
data from these infusions was reported previously 
(Carroll et al., 1980). 
On the evening prior to the infusion, subjects 
were hospitalized at the Clinical Research Center 
at the University of Michigan Medical Center and 
an indwelling venous catheter was inserted. The 
following day, all subjects received 0.7551 .O mg 
intravenously of methscopolamine bromide, a peri- 
pheral cholinergic blocker without significant 
central effects. This drug was used to prevent 
peripheral cholinomimetic toxicity from physostig- 
mine. This dose of methscopolamine promptly 
produced tachycardia in all subjects; the pulse rate 
was monitored and methscopalamine was readmin- 
istered at doses of 0.1-0.2 mg intravenously if 
cardiac rate decreased below lOO/min. We then 
infused 2-4 mg of physostigmine salicylate intrave- 
nously in 200 ml of normal saline over a 40 min 
period. In this study, no systematic placebo control 
infusions were employed for comparison. 
One of us (JFG) completed the Rater Activati- 
on-Inhibition Scale (Janowsky et al., 1973) at 15- 
min intervals throughout the physostigmine infu- 
sion. Ratings were conducted in a single-blind 
manner; while the rater was not blinded, subjects 
were unaware of the timing of the infusion. The 
inhibition scale was developed by Janowsky et al. 
(1973) to evaluate the general ‘anergic-inhibitory’ 
effects of physostigmine and evaluates subjects on 
a scale of O-5 along the following dimensions: 
(1) irritable, (2) lethargic, (3) dysphoric, (4) slow 
thoughts, (5) wants to say nothing, (6) hostile, 
(7) withdrawn, (8) wants to be alone, (9) apathetic, 
(I 0) crying, (I 1) sad, (I 2) lacks energy, (13) sleepy, 
(14) drained, (15) hypoactive, (16) lacks thoughts, 
(17) motor retardation, (18) psychotic, (19) angry, 
(20) emotionally withdrawn. Additionally, the 
following items are similarly scored and constitute 
the activation scale: (21) cheerful, (22) friendly, 
(23) interacting, (24) talkative. Scores on these 
24 items were compared between the pre- 
physostigmine phase and the point of maximal 
symptoms following physostigmine infusion, using 
the Student’s paired t-test. Verbal observations 
made by subjects over the course of the study were 
transcribed; we then identified any statements 
reflecting cognition, mood, or psychomotor inhibi- 
tion and activation. For comparisons with the 
negative schizophrenic syndrome, subscales from 
the Scale for the Assessment of Negative Symp- 
toms (SANS, Andreasen, 1983) were utilized. 
RESULTS 
All subjects showed a similar response to the 
physostigmine infusion. After a brief mild anxiety 
state, usually described as ‘nervousness’, features 
of psychomotor retardation became evident about 
20 min following the onset of infusion. Subjects 
described themselves as ‘drained’, became apa- 
thetic, experienced all their mental processes as 
‘slowed down’, were reluctant to talk, and reported 
a paucity of ideas. These symptoms increased in 
intensity to a peak at about 30 min before reaching 
a plateau, and returned to baseline about 60-90 
min following onset of the infusion. Only three of 
our seven patients reported nausea, but not until 
after the peak of the observed behavioral changes. 
Observer ratings on the following behavioral 
items increased significantly (p < 0.05) after physo- 
stigmine infusion: withdrawn; apathetic; lacks 
energy; drained; hypoactive; lethargic; motor 
retarded; slow thoughts; wants to say nothing; 
wants to be alone; sleepy; lacks thoughts; emotion- 
ally withdrawn. Ratings on the following items 
decreased significantly: interacting; talkative; 
cheerful. Ratings on the following items did not 
change significantly: irritable; hostile; crying; sad; 
psychotic; angry; friendly. This profile is strikingly 
consistent with that reported in prior physostig- 
mine studies. None of the subjects reported sadness 
or depression, and none cried or admitted to 
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irritability, nor did any express feelings of hopeless- 
ness, worthlessness, or guilt. 
Both observer ratings and subject self-reports 
revealed that major components of the negative 
schizophrenic syndrome (affective flattening, 
alogia, avolition-apathy, and anhedonia) were pre- 
sent following physostigmine. On the other hand, 
distinctive depressive features (such as sadness, 
crying, guilt, etc.) were not noted. 
DISCUSSION 
The results of this study indicate that the behav- 
ioral effects of intravenous physostigmine closely 
resemble many of the features of the negative 
schizophrenic syndrome. Normal subjects became 
withdrawn, apathetic, hypoactive, lethargic, motor 
retarded, they desired to be alone, were emotion- 
ally detached, and had slowing of thoughts, speech, 
and motility; these features occurred in the absence 
of significant mood changes. In view of the absence 
of a control comparison group (no placebo infu- 
sions) and the single-blind study design, however, 
caution is warranted in the interpretation of 
these data. 
The ‘physostigmine syndrome’ has been rela- 
tively well studied. The detailed studies by Janow- 
sky et al. (1973, 1974, 1986) have been replicated 
by others (Modestin et al., 1973; Davis et al., 1976; 
Risch et al., 1981) and there is general agreement 
that the drug consistently induces withdrawal, 
apathy, and related symptoms in normal subjects. 
There is, however, some continued uncertainty 
about whether it may initiate legitimate depressive 
mood in normal individuals. One study (Risch 
et al., 1981) seems to suggest this, while another 
(Davis et al., 1976) agrees with our findings by 
failing to note any significant increases in depres- 
sive mood following the infusion. However, physo- 
stigmine is a somewhat ‘dirty’ drug pharmacolog- 
ically with both muscarinic and nicotinic properties 
(and the nicotinic system can modulate monoami- 
nergic and other neurotransmitter systems); conse- 
quently, interpretation of physostigmine effects in 
pure muscarinic cholinergic terms is flawed and 
limited. 
The possible role of acetylcholine in schizophre- 
nia is intriguing but sketchy and controversial 
(Tandon and Greden, 1989; 1990). Results of 
various studies do little more than provide substan- 
tiation that the cholinergic system may be involved 
in ‘some schizophrenic symptoms’. While some 
studies report brief beneficial effects of cholinomi- 
metic agents in schizophrenia (Pfeiffer and Jenney, 
1957; Rosenthal and Bigelow, 1973), others report 
a worsening of schizophrenic symptomatology 
(Rowntree et al., 1950). It should be noted that 
these evaluations of the cholinergic system in 
schizophrenia were conducted before investigators 
began categorizing schizophrenic symptoms speci- 
fically as ‘positive’ and ‘negative’; modulation of 
the cholinergic system may have opposite effects 
on positive and negative symptoms (Tandon and 
Greden, 1989) and this may provide a partial 
explanation for the somewhat contradictory find- 
ings in previous studies of the cholinergic system 
in schizophrenia. 
More recently, there have been suggestions that 
anticholinergic agents may antagonize some thera- 
peutic effects of neuroleptics, with selective 
exacerbation of the cluster of positive psychotic 
symptoms but without any reported adverse effects 
on negative symptomatology (Johnstone et al., 
1983; Singh et al., 1987). Other studies have high- 
lighted the benefits of continued antiparkinsonian 
medication in chronic schizophrenic patients, and 
have noted increased subjective distress and 
‘depressive’ symptomatology following their with- 
drawal (Manos et al., 1981; Jellinek et al., 1981). 
There also have been several case reports of schizo- 
phrenic patients abusing anticholinergic drugs, 
with most patients reporting mood-elevating, ener- 
gizing, stimulating, and socializing effects of these 
agents (Fisch, 1987; Wells et al., 1989). We con- 
ducted a pilot study (Tandon et al., 1988) by 
administering 10 mg/day trihexiphenidyl to five 
chronic schizophrenic patients with predominantly 
negative symptoms; these patients were stabilized 
on neuroleptic agents without extrapyramidal side- 
effects or tardive dyskinesia. Improvement was 
noted in four of the five patients, as measured by 
the BPRS (Overall and Gorham, 1962) and the 
SANS (Andreasen, 1983) with significant amelio- 
ration noted in the areas of affective flattening, 
anhedonia-asociality, and avolition-apathy. In a 
recent study on the effects of biperiden (an anticho- 
linergic agent) on positive and negative symptoms 
in thirty medication-free schizophrenic patients 
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(Tandon et al., 1991a), we observed a significant 
decrease in negative symptom severity following 
biperiden. 
There may be a pattern in these scattered 
reports: administration of an anticholinesterase to 
normal subjects may induce a clinical profile that 
resembles many of the key features associated with 
negative schizophrenia; cholinomimetic agents 
may intensify selected negative schizophrenic 
symptoms in patients with the syndrome; anticho- 
linergic agents may relieve them; some schizophre- 
nic patients may experience energizing, stimulating 
effects from anticholinergic drugs, and may thus 
‘abuse’ them. 
These checkered pieces of data suggest that 
cholinergic hyperactivity might be implicated in 
the pathogenesis of negative schizophrenic symp- 
toms (Tandon and Greden, 1989; 1990). Although 
the evidence is preliminary and somewhat specula- 
tive, this prospect clearly warrants further investi- 
gation. This hypothesis is not incompatible with 
prior formulations that cholinergic hyperactivity 
may be implicated in the pathogenesis of affective 
dysregulation. Instead, it dramatizes the impor- 
tance of considering phenomenology in study 
design, and not restricting ourselves to current 
nosological classification schemes. The mechanism 
of cholinergic overdrive may be involved in both 
the negative schizophrenic syndrome and certain 
aspects of the depressive syndrome; this may pro- 
vide a partial explanation for the phenomenologi- 
cal similarity between these syndromes and the 
frequent difficulty in differentiating between them. 
The common mechanism of cholinergic hyperactiv- 
ity may also serve to explain some similar neurobi- 
ological abnormalities in schizophrenia and major 
depression (Tandon et al., 199la; Tandon et al.. 
199lb; Riemann et al., 1991; Tandon et al., 1992). 
In view of the converging suggestive evidence but 
somewhat speculative nature of the hypothesis, a 
systematic comparison of the role of the cholinergic 
system in the pathophysiology of schizophrenia 
and major depression is warranted. 
REFERENCES 
Andreasen, N.C. (1982) Negative symptoms in schizophrenia: 
definition and reliability. Arch. Gen. Psychiatry 39. 784-788. 
Andreasen, N.C. (1983): Scale for the Assessment of Negative 
Symptoms (SANS). Iowa City, University of Iowa. 
Carroll, B.J., Greden, J.F., Haskett. R.F., Feinberg, M., Albala, 
A.A., Martin, F.I.R., Rubin, R.T., Heath, B., Sharp, P.T., 
McLeod, W.L. and McLeod, M.F. (1980) Neurotransmitter 
studies of neuroendocrine pathology in depression. Acta 
Psychiatr. Stand. Suppl. 280. 1833199. 
Crow, T.J. (I 980) Molecular pathology of schizophrenia: more 
than one disease process? Br. Med. J. 280, l-9. 
Davis, K.L.. Hollister L.E., Overall J., Johnson, A. and 
Train, K. (1976) Physostigmine: effects on cognition and 
affect in normal subjects. Psychopharmacology 5 I, 23-27. 
Dilsaver, S.C. (1986) Cholinergic mechanisms in depression. 
Brain Res. Rev. I I, 2855316. 
Fisch. R.Z. (1987) Trihexiphenidyl abuse: therapeutic implica- 
tions for negative symptoms of schizophrenia. Acta Psychi- 
atr. Stand. 75, 91-94. 
@eden. J.F. and Tandon. R. (1990) Introduction. In Greden, 
J.F., Tandon, R. (Eds.) Negative Schizophrenic Symptoms: 
Pathophysiology and Clinical Implications. American Psychi- 
atric Press, Washington DC, pp. xxv-xxix. 
Janowsky, D.S., El-Yousef, M.K., Davis, J.M. and Sekerke, 
J.H. (1973) Parasympathetic suppression of manic symptoms 
by physostigmine. Arch. Gen. Psychiatry 28, 5422547. 
Janowsky, D.S., El-Yousef, M.K. and Davis, J.M. (1974) 
Acetylcholine and depression. Psychosom. Med. 36,248256. 
Janowsky, D.S., Risch, SC., Kennedy, B.. Ziegler, M. and 
Huey. L. (I 986) Central muscarinic effects on mood, cardio- 
vascular function, pituitary and adrenal neuroendocrine 
release. Psychopharmacology 89, 150-l 54. 
Jellinek, T., Gardos, G. and Cole, J.O. (1981) Adverse effects 
of antiparkinson drug withdrawal. Am. J. Psychiatry 138, 
1567-1571. 
Johnstone, E.C., Crow, T.J., Ferrier, I.N., Frith, C.D.. Owens, 
D.G.C., Bourne, R.C. and Gamble, S.J. (1983) Adverse 
effects of anticholinergic medication on positive schizophre- 
nic symptoms. Psychol. Med. 1983; 13. 513-527. 
Manos, N., Gkiouzepas, J., Tzotzoras, T. and Tzanetoglou 
(198 I) Gradual withdrawal of antiparkinson medication in 
chronic schizophrenics: Any better than the abrupt? J. Nerv. 
Mental Dis. 169, 6599661. 
Modestin, J.. Hunger, J. and Schwartz, R.B. (1973) Uber dte 
depressogene Wirkung von physostigmin. Arch. Psychiatric 
Nervenkrankh. 218, 67-70. 
Overall, J.E. and Gorham, D.R. (1962) The Brief Psychiatric 
Rating Scale. Psychiatric Reports 10. 7999812. 
Pfeiffer, CC. and Jenney, E.H. (1957) The inhibition of the 
conditioned response and the counteraction of schizophrenia 
by muscarinic stimulation of the brain. Ann. NY Acad. Sci. 
66, 7533764. 
Riemann, D., Gann, H.. Fleckenstein, P., Hohagen, F., 
Olbrich, R. and Berger, M. (1991) Effect of RS-86 on REM 
latency in schizophrenia. Psychiatry Res. 38, 89-92. 
Risch. SC., Cohen, R.M., Janowsky, D.S.. Kalin. N.H., 
Sitaram, N., Gillin, J.C. and Murphy, D.L. (1981) Physostig- 
mine induction of depressive symptomatology in normal 
human subjects. Psychiatry Res. 4, 89-94. 
Rosenthal, R. and Bigelow, L.G. (1973) The effects of physo- 
stigmine in phenothiazine resistant chronic schizophrenic 
23 
patients: preliminary observations. Compr. Psychiatry 14. 
4899494. 
Rowntree, D.W., Nevin, S. and Wilson, A. (1950) The effects 
of diisopropylfluorophosphonate in schizophrenia and 
manic-depressive psychosis. J. Neurol. Neurosurg. Psychiatry 
13, 47762. 
Singh, M.M., Kay, S.R. and Opler, L.A. (1987) Anticholiner- 
gic-neuroleptic antagonism in terms of positive and negative 
symptoms of schizophrenia: implications for psychobiologi- 
cal subtyping. Psychol. Med. 17, 37-48. 
Strauss, J.S., Carpenter, W.T. Jr. and Bartko, J.J. (1974) 
Schizophrenic signs and symptoms. Schizophr. Bull. 1974; 
4, 61-69. 
Tandon, R. and Greden. J.F. (1989) Cholinergic hyperactivity 
and negative schizophrenic symptoms: a model of 
dopaminergic/chohnergic interactions in schizophrenia. 
Arch. Gen. Psychiatry 1989; 46, 745-753. 
Tandon, R. and Greden. J.F. (1990) Cholinergic excess and the 
negative schizophrenic syndrome. In Negative Schizophrenic 
Symptoms: Pathophysiology and Clinical Implications. 
Greden, J.F., Tandon, R. (Eds.) American Psychiatric Press, 
Washington DC, pp. 99-l I I, 
Tandon, R., Greden, J.F. and Silk, K.R. (1988) Treatment of. 
negative schizophrenic symptoms with trihexiphenidyl. 
J. Clin. Psychopharmacol. 8, 212-215. 
Tandon, R.. Greden. J.F., Goodson, J., Shipley, J.E., Mann, N. 
and Eisner, W.H. (1991a) Muscarinic hyperactivity in schizo- 
phrenia: relationship to positive and negative symptoms. 
Schizophr. Res. 4, 23-30. 
Tandon, R.. Mazzara, C., DeQuardo, J.R., Craig, K.A., 
Meador-Woodruff, J.H., Goldman, R. and Greden, J.F. 
(1991 b) Dexamethasone suppression test in schizophrenia: 
relationship to symptomatology, ventricular enlargement, 
and outcome. Biol. Psychiatry 29, 9533964. 
Tandon, R., Shipley, J.E., Taylor, S., Greden, J.F., Eiser, A., 
DeQuardo, J.R. and Goodson. J. (1992) Electroencephalo- 
graphic sleep abnormalities in schizophrenia. Arch. Gen. 
Psychiatry 49, 1855194. 
Wells, B.G., Marken, P.A., Rickman, L.A., Brown, C.S., 
Hamann, G. and Grimmig, J. (1989) Characterizing anticho- 
linergic abuse in community mental health. J. Clin. Psycho- 
pharmacol. 9, 43 l-435. 
